Karine Tawagi: New U.S. FDA approval for Enzalutamide in BCR prostate cancer

Karine Tawagi, Assistant Professor of Clinical Medicine and Associate Program Director at the University of Illinois, Chicago, recently shared on X/Twitter:

“New U.S. FDA approval for Enzalutamide in BCR prostate cancer:
– Patients with BCR post-prostatectomy and/or RT, PSA DBT <=9 months, not candidate for salvage RT.
– MFS at 5 years: 87.3% for enzalutamide/ADT vs 80.0% for Enzalutamide alone vs 71.4% for ADT alone.
– OS immature
– AEs: hot flash, MSK, fatigue.”

Source: Karine Tawagi/Twitter